Lekarstvennaya terapiya limfomy Khodzhkina


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hodgkin's lymphoma (HL) is a high-curable malignant disease. Modern chemoradiation therapy can induce complete remission (CR) in 80-95 % of patients with Hodgkin's lymphoma, and the 5-year overall survival (OS) is greater than 80-90 %. ABVD chemotherapy regimen is the «gold» standard in the treatment of primary Hodgkin's lymphoma and is characterized by an optimal ratio of efficacy and toxicity compared with other chemotherapy regimens. Treatment Scheme escalated-dose BEACOPP is more effective in advanced stages of Hodgkin's lymphoma with high risk of recurrence (IPS 4-7). Currently, the potentials for the reduction of toxicity of escalated-dose BEACOPP in advanced stages of Hodgkin's lymphoma are evaluated. Escalated-dose BEACOPP improves OS, reduces the incidence of early recurrence compared to other regimens. Modern therapy of HL should be directed to the complete cure using first-line treatment with maximum efficiency and minimal toxicity.

Full Text

Restricted Access

About the authors

L. V Filatova

Email: Larisa_Filatova@list.ru

References

  1. Харченко В.П., Даценко П.В., Паньшин Г.А. и др. Пятилетние результаты нового режима химиотерапии CEA/ABVD в рамках комбинированного лечения распространенной лимфомы Ходжкина (неблагоприятная прогностическая группа) // Вопр. онкол. 2006. № 5. С. 531–37.
  2. Barrington SF, Qian W, Somer EJ, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824–33.
  3. Bartlett NL, Niedzwiecki D, Johnson L, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007;18:1071–79.
  4. Borchmann P, Diehl V, Goergen H, et al. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial. 2010;95:473.
  5. Brepoels L, Stroobants S, Verhoef G. PET and PET/CT for response evaluation in lymphoma: Сurrent practice and developments. Leuk Lymph 2007;48:270–82.
  6. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Brit J Haemtol 2008;141:3–13.
  7. Canellos GP, Anderson JR, Propert JR, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–84.
  8. Canellos GP, Gollub J, Neuberg D, et al. Primary systemic treatment of advanced Hodgkin’s disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 2003;14:268–72.
  9. Cheson BD, Horning SJ, Coiffier B. et al. Report of an International Workshop to standardize response criteria for Non-Hodgkin’s lymphomas. J Clin Oncol 1999;17:1244–53.
  10. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma J Clin Oncol 2007;25:579–586.
  11. Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy: comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD, a report from the NCI of Canada clinical trials group. J Clin Oncol 1997;17:1638-45.
  12. De Vita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970;73:881-95.
  13. Diehl V, Franklin J, Pfreundschuh M. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95.
  14. Duggan DB, Petroni FR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14.
  15. Engert A, Diehl V, Franclin J. et al. Escaleted-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-54.
  16. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD 15 trial): a randomized, open-label, phase 3 non-inferiority trial. The Lancet 2012;379:1791-99.
  17. Federico M, Luminari S, lannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-11.
  18. Franklin J, Diehl V. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG. Ann Oncol 2002;13:98-101.
  19. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standart therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologia 2006;91:475-81.
  20. Gianni AM, Rambaldi A, Zinzani PL, et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy plus preplanned high dose salvage in advanced stage Hodgkin lymphoma: A randomized trial of the Michaelangelo, GITIL and IIL cooperative groups. Proc ASCO J Clin Oncol 2008;26:Abstract 8506.
  21. Gobbi PG, Pieresca C, Federico M, et al. MOPP/ EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: A report from the Italian Lymphoma Study Group. J Clin Oncol 1993;11:712-19.
  22. Gobbi PG, Pieresca C, Ghirardelli ML. et al. Longterm results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 1998;91:2704-12.
  23. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14.
  24. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-37.
  25. Martinelli G, Cocorocchio E, Peccatori F, et al. ChlVPP/ABVVP a firstline hybrid combination chemotherapy for advanced Hodgkin's lymphoma: A retrospective analysis. Br J Haematol 2004;125:584-89.
  26. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
  27. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-71.
  28. Sieber M, Tesch H, Pfistner B, et al. Treatment of advanced Hodgkin's disease with COPP/ ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: Final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 2004;15:276-82.
  29. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996;14:603-09.
  30. Viviani S, Bonfante V, Santoro A, et al. Longterm results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer 1999;5:275-82.
  31. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985; 21:601-05.
  32. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203-12.
  33. Wedgwood AR, Fanale MA, Fayad LE, et al. Rituximab + ABVD improves event free survival in patients with classical Hodgkin lymphoma who have PET positive disease after 2-3 cycles of therapy. Haematologica 2007;92:75.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media